What is EGRX's P/E ratio?

Eagle Pharmaceuticals Inc (EGRX) currently trades at a P/E ratio of 0.17.

Eagle Pharmaceuticals Inc reports a Return on Equity (ROE) of 6.18%.

What is EGRX's dividend yield?

Eagle Pharmaceuticals Inc offers a dividend yield of 0.00%.

What is EGRX's Quality Score?

Our AI rates EGRX's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy EGRX?

Our AI Timing Score for EGRX is 4 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does EGRX belong to?

Eagle Pharmaceuticals Inc is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange

Eagle Pharmaceuticals Inc (EGRX) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-23 | FS: 2023-06-30)

EGRX AI Analysis Summary

Our AI summary for EGRX: Eagle Pharmaceuticals Inc (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 0.17, ROE of 6.18%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 4/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

EGRX

Eagle Pharmaceuticals Inc

USD 0.37

-0.01 (-1.64%) Day Change

Watchlist Portfolio Compare Chart

0.17

P/E

0.28

D/E

6.2%

ROE

3.9%

ROA

0.00%

Div Yield

EAGLE PHARMACEUTICALS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 0.37 Price -0.01 (-1.64%) Day Change	NEWS SCORE: 99

EGRX, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...

No price data to display chart for the last 3-months of this stock

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not quite good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

52%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	99
Magic Formula Rank by ROA	131
Magic Formula Rank by ROE	131
Magic Formula Rank by ROIC	100 GOOD
Price	0.37
PBV / Sector	0.01 / 10.19 GREAT
Earning Per Share	1.75

PE / Sector	0.17 / 31.74 GREAT
PEG or PE/Growth / Sector	N/A / -0.02
Average 1M Daily Value	1050.243825000000
Average 1W Daily Value	3312.479000000000

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

58%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	6.04 / 12.63
NPM Average (%) / Sector	5.19 / -10.74
NPM Change Average (%) / Sector	-140.39 / 114.91
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	3.85 / 7.67
ROA Average (%) / Sector	3.92 / 2.97
ROA Change Average (%) / Sector	-150.47 / 112.43
ROE (%) / Sector	6.18 / 25.75
ROE Average (%) / Sector	6.20 / 14.00
ROE Change Average (%) / Sector	-166.71 / 378.64
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.52
Dividend Average (%) / Sector	N/A / 3.06
Dividend Change Average (%) / Sector	N/A / 13.74

Registration Details

Analyze Date	2026-08-06 07:59:55
Symbol	EGRX
Name	EAGLE PHARMACEUTICALS INC
Sector	Healthcare >> Drug Manufacturers - Specialty & Generic
Market	NASDAQ
Listed Shares	13.16 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	3.29 / 10,556.24

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 50 Tice Boulevard, Woodcliff Lake, NJ, United States, 07677

Phone: 201 326 5300

Website: https://www.eagleus.com

Employees: 134

Sector: Healthcare >> Drug Manufacturers - Specialty & Generic

Description: Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an anti-toxin agent in Phase 2 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs; ENA-001 developed by Enalare, an agnostic respiratory stimulant for respiratory depression; EA-114, novel and proprietary formulation of fulvestrant developed for hormone-receptor-positive (HR+) metastatic breast cancer. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.